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Abstract
Background: Small cell carcinoma of the cervix (SCCC) is a very rare tumor. Due to its rarity and the long time period, there
is a paucity of information pertaining to prognostic factors associated with survival. The objective of this study was to
determine whether clinicopathologic finings or immunohistochemical presence of molecular markers predictive of clinical
outcome in patients with SCCC.
Methodology and Findings: We retrospectively reviewed a total of 293 patients with SCCC (47 patients from Cancer Center
of Sun Yat-sen University in china, 71 patients from case report of china journal, 175 patients from case report in PubMed
database). Of those 293 patients with SCCC, the median survival time is 23 months. The 3-year overall survival rates (OS) and
3-year disease-free survival rates (DFS) for all patients were 34.5% and 31.1%, respectively. Univariate and multivariate
analysis showed that FIGO stage (IIb–IV VS I–IIa, Hazard Ratio (HR)=3.08, 95% confidence interval (CI) of ratio=[2.05, 4.63],
P,0.001), tumor mass size ($4c mV S,4 cm, HR=2.37, 95% CI=[1.28, 4.36], P=0.006) and chromogranin A (CgA) (Positive
VS Negative, HR=1.81, 95% CI=[1.12, 2.91], P=0.015) were predictive of poor prognosis. CgA stained positive was found to
be highly predictive of death in early-stage (FIGO I–IIa) patient specifically.
Conclusions: Patients with SCCC have poor prognosis. FIGO stage, tumor mass size and CgA stained positive may act as a
surrogate for factors prognostic of survival. CgA may serve as a useful marker in prognostic evaluation for early-stage
patients with SCCC.
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Introduction
Neuroendocrine small cell cervical carcinoma is an aggressive,
but rare form of cervical cancer with an incidence of less than 3%
of all cervical cancers [1–3]. These tumors are characterized by a
high incidence of early nodal and distant metastases, resulting in
poorer prognosis than other subtypes of cervical cancers [4–6]. In
previous studies, 60.0–82.0% of small cell cervical carcinomas had
lymph-vascular space infiltration or pelvic lymph node metastasis
at the time of diagnosis [7–9]. Moreover, small cell cervical
carcinoma exhibits a propensity for rapid distant metastasis to sites
including the lung, liver, brain, bone, pancreas, and lymph nodes,
resulting in treatment failure in most cases [8–11].
Most patients die as a result of early metastasis via the
bloodstream and recurrences usually occur within 2 years. Given
the poor prognosis, it is important to identify prognostic factors
responsible for survival in an effort to improve treatment
strategies. However, due to its rarity and the long time period
required to enroll a sufficient number of patients, most studies on
SCCC are comprised of only small series and case reports, making
it difficult to perform a randomized, controlled clinical trial to
determine optimal therapy and draw conclusions on overall
management. To determine the prognostic factors of this rare
tumor, we pooled cases from our own institution with all the
reported cases in the literature from PubMed database and china
journal to perform a meta-analysis.
Materials and Methods
Ethics Statement
All the 47 patients from Cancer Center, Sun Yat-Sen University
agreedtoparticipateinthestudyandgavewritteninformedconsent.
ThisstudywasapprovedbythemedicalethicscommitteeofCancer
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e33674CenterofSunYat-SenUniversityandcompliedwiththedeclaration
of Helsinki.
Samples and Cases
In this study, a total of 293 patients with SCCC were enrolled.
Forty-seven patients with SCCC who received diagnoses from
1998–2009 were identified from gynecology department of Cancer
Center, Sun Yat-sen University, Guangzhou, China. The
Figure 1. Relationship between clinicopathologic variables and SCCC patient survival. (A. B): Overall survival (OS) and disease free
survival (DFS) base on all 293 patients with Small cell carcinoma of the cervix (SCCC). (C. D): OS and DFS based on International Federation of
Gynecology and Obstetricsstage (FIGO) stage. (E. F): OS and DFS based on tumor size. (G. H): OS and DFS based on chromogranin A (CgA) express.
doi:10.1371/journal.pone.0033674.g001
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the literature from PubMed database and china journal. All
patients were selected based on the following criteria: availability
of conclusive histopathologic diagnosis as SCCC; no previous
malignant disease or a second primary tumor; with complete
clinical pathology and follow-up data; the immunostainings were
done in the cases under the identical conditions and use the same
scoring method. Cases with not good enough data or different
immunohistochemistry method were excluded from our study to
provide relative accurate data for meta-analysis. (Table S1).
Patient and disease characteristics, including age of diagnosis,
Federation Internationale Gynecologica Obstetrica (FIGO) stage,
lymph node involvement, lymph-vascular space invasion, tumor
size, depth of stromal invasion and the stained status of Neurone-
specific enolase (NSE), Chromogranin A (CgA), Synaptophysin
(SYN), were evaluated.
Immunohistochemistry (IHC)
Paraffin-embedded, archived SCCC samples obtained from 40
patients (7 patients received preoperative radiotherapy and/or
chemotherapy were excluded.) were histologically and clinically
diagnosed from the Cancer Center, Sun Yat-Sen University. IHC
staining (NSE (DAKO; 1:500), SYN (DAKO; 1:300), CgA
(DAKO; 1:300)) was carried out on 4-um sections. The detailed
staining procedures were performed according to the reference
‘‘Zheng M et al., Obstet Gynecol 2010’’ [12]. Briefly, Sections
were deparaffinized in xylene and rehydrated in graded ethanol
and distilled water before being heated in a microwave in Tris-
EDTA for 25 min. Endogenous peroxidase activity of the samples
was blocked by incubating the slides in 3% hydrogen peroxide
(H2O2) in methanol for 15 min. Incubation the first antibody
overnight at 4uC. A biotin-conjugated goat anti-rabbit IgG
secondary antibody (ZhongSan-JingQiao Biologic Technology
Co., Beijing, China) was then applied for 15 min at 37uC. The
last, all sections were stained in DAB for the same duration of
time. Immunoreactivity was described by the percentage of
positive tumor cells (percent positivity) and by the staining
intensity (weak, moderate, strong). Slides given scores of (2)o r
(+) were recorded as negative, and slides given scores of (++) and
(+++) were recorded as positive. All results were confirmed by
more than 2 pathologists in a double-blind analysis. The majority
of the 246 cases selected from the literature were analysed with the
same or a similar immunohistochemical method (Table S2). For
the others no indication was found.
Statistical analysis
The association of CgA protein expression with SCCC patient’s
clinicopathologic features and the correlations between molecular
features detected with each other were assessed by the chi-square
test. Overall survival (OS) and disease-free survival (DFS) were
evaluated using the Kaplan–Meier method and log-rank tests. The
Cox proportional hazards model was used to estimate the
independent factors prognostic for OS and DFS. All analyses
were carried out using SPSS software (version 13.0, SPSS Inc.,
Chicago, IL). Two-sided P values of ,0.05 were considered to
indicate statistical significance. The end points of all 47 patients
from Cancer Center, Sun Yat-sen University were updated in
March 2011.
Results
Clinicopathologic features
The two hundred and ninety three patients were ranged in age
from 18 to 83 years with a median of 40 years. Abnormal vaginal
bleeding or vaginal discharge at presentation was noted in 75.9%
of patients, 11.4% had abdominal or back pain, 2.2% had general
weakness and swelling, 10.5% had no symptom. One hundred and
fifty five patients (54.6%, 155/284) had FIGO stage I, 89 (31.3%,
89/284) had stage II, 24 (8.5%, 24/284) had stage III, and 16
(5.6%, 16/284) had stage IV. One hundred and thirty two (70.2%)
patients had a pure histologic type composed of SCCC and 56
(29.8%) had a mixed histologic pattern associated with squamous
cell carcinoma or adenocarcinoma in addition to the SCCC
component. Sixty five patients (54.2%, 65/120) have lymph-
vascular space infiltration and 87 (47.0%, 87/185) have lymph
node metastasis in this study. However, 60.0–82.0% SCCC
patients had lymph-vascular space infiltration or pelvic lymph
node metastasis at the time of diagnosis in previous studies [7–9].
Other clinicopathologic characteristics are shown in Table S3.
Relationship between clinicopathologic variables and
SCCC patient survival
The 3-year OS rates and 3-year DFS rates for all 293 patients
were 34.5% and 31.1%, respectively (Figure 1. A. B). The
median survival time for all patients was 23 months (range, 1–264
Figure 2. Immunohistochemical analyses of chromogranin A
(CgA) staining in Small cell carcinoma of the cervix tissues. As
can be seen, CgA shows no positive staining (2)(case-431901; A: x200;
B: x400), weakly positive staining (+) (case-385737; C: x200; D: x400),
moderate staining (++) (case-449570; E: x200; F: x400), strong staining
(+++) (case-437412; G: x200; H: x400) in Small cell carcinoma of the
cervix tissues.
doi:10.1371/journal.pone.0033674.g002
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were 34 months and 13 months, respectively (P,0.001) (Figure 1.
C. D). Patients without lymph node metastases had a 3-year OS
rates of 54.1%, compared with 23.4% for patients with lymph
node metastases (P,0.001); Patients with tumors ,4 cm had a 3-
year OS rates of 58.4% vs 20.1% in those with larger tumors
(P,0.001) (Figure 1. E. F). In contrast, age (P=0.270), lymph
vascular space invasion (P=0.214), tumor homology (P=0.499)
and NSE stained positive (P=0.426) were not prognostic for
survival. Although not statistically significant, CgA stained positive
was tended to adversely affect survival. Patients with CgA stained
positive had a 3-year survival rate of 46.8%, compared with 30.0%
for patients with CgA stained negative (P=0.053) (Figure 1. G.
H).
Relationship between CgA expression and SCCC patient
survival based on IHC
Immunohistochemical assay showed that NSE was positive in
36 tumors (90.0%, 36/40), CgA in 27 tumors (67.5%, 27/40), and
SYN in 25 tumors (62.5%, 25/40). Among, negative CgA
expression (2/+) was observed in 13 SCCC specimens, with 8/
40 (20.0%) labeled as (2) and 5/40 (12.5%) labeled as (+). In
contrast, 27/40 (67.5%) SCCC specimens labeled with CgA
expression levels of (++)o r( +++) were recorded as positive
(Figure 2). Univariate Cox analysis of the presence of
neuroendocrine markers revealed that CgA was a poor prognostic
factor (P=0.003). Patient with CgA stained positive had poor
survival (Figure 3. A. B), while SYN and NSE showed no impact
on survival. Further analysis combined all 293 patients showed
that CgA stained positive were significant predictors of poor
survival in early-stage (FIGO I–IIa) patient specifically (P,0.05)
Figure 3. Survival curves stratified by chromogranin A (CgA) levels according to International Federation of Gynecology and
Obstetricsstage (FIGO) stage. (A. B): The differences of overall survival and disease free survival curves according to CgA expression were seen in
40 patients from Cancer Center of Sun Yat-sen University in china. (C. D): In FIGO stage I–IIa classification panel, patients with CgA stained negative
show much better overall survival and disease free survival. (E. F): In FIGO stage IIb–IV classification panel, patients with CgA stained negative not
show much better overall survival and disease free survival.
doi:10.1371/journal.pone.0033674.g003
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(Figure 3. E. F).
Univariate and multivariate Cox analysis of all 293 SCCC
patients to determine the poor prognostic factor
To identify factors prognostic for survival, we examined overall
survival using Cox regression proportional hazard analyses.
Univariate Cox regression analysis showed that FIGO stage
(P,0.001), tumor mass size (P,0.001), lymph node metastasis
(P,0.001), depth of stromal invasion (P=0.022), and CgA stained
positive (P=0.034) were associated with prognostic of patients
with SCCC. In contrast, age, tumor homology, lymph-vascular
space invasion, NSE stained positive and SYN stained positive
were not prognostic for survival (P.0.05) (Table 1). After adjusting
for potential confounding factors, analyses using multivariate Cox
regression model showed that FIGO stage of disease (HR, 3.08;
95% CI, 2.05–4.63; P,0.001), tumor mass size (HR, 2.37;
95% CI, 1.28–4.36; P=0.006) and CgA stained positive (HR,
1.81; 95% CI, 1.12–2.91; P=0.015) remained as significant
independent prognostic factors for survival. Other factors, such
as lymph node metastases, and depth of stromal invasion, were not
significant independent prognostic factors for survival (Table 1).
Discussion
Small cell carcinoma of the uterine cervix is an uncommon
malignancy, accounting for 0.5–3.0% of all cervical cancers, is
referred to by various names, such as small cell neuroendocrine
tumor, small cell undifferentiated carcinoma, small cell carcinoma,
argyrophilic cell carcinoma, and endocrine intermediate cell
carcinoma. Similar to small cell lung cancer, cervical small cell
carcinoma is difficult to manage and usually follows an aggressive
clinical course, with death within a few years after diagnosis. The
Gynecologic Oncology Group attempted to study small cell
cervical carcinoma, but failed to recruit sufficient numbers of
patients. As a result, treatment decisions have been based on these
small single institution studies, and have extrapolated treatment
approaches from the management of small cell cancer of the lung.
The prognosis of SCCC is considered similar to that of small cell
cancer of the lung, but long-term survival in SCCC patient has
been reported [13–15]. To identify the clinical and pathologic
factors prognostic of survival, and to determine optimal treatment
strategies for patients with SCCC, 293 patients with SCCC
reported in this study. To our knowledge, this is the largest study
to date that analyzes the clinicopathologic and molecular markers
associated survival outcomes.
Our data showed that early-stage disease is an independent
prognostic factor. We observed a 3-year survival rate for all
patients with SCCC of 34.5%, those with stage I–IIA disease had a
3-year survival of 48.4% compared with 13.0% for those with
stage IIB–IV. Consistent with previous reports, the overall 3-year
survivals ranged from approximately 50.0% for stage I patients,
40.0% for stage II patients, 25.0% for stage III patients, and under
10.0% for stage IV patients. In the current study, tumor size was
also found to have a marginal significance in multivariate analysis
(HR, 2.37; 95% CI, 1.28–4.36; P=0.006). In fact, all these
patients who were alive without evidence of disease at the time of
last follow up were diagnosed at an early stage with lesions ,2 cm.
Similarly, Sheets et al. showed that patients with tumors ,2c m
had longer progression-free survival than patients with .2c m
lesions [16]. With more patients, FIGO stage and tumor size were
confirmed important in this rare cervical malignancy in our study
and may ultimately prove to be an important independent
prognostic predictor for survival.
Chromogranin A (CgA) is an acidic glycoprotein belonging to a
family of regulated secretory proteins stored in the dense core
granules of the adrenal medulla and of many other neuroendo-
crine cells and neurons. This protein is frequently used as a
diagnostic and prognostic serum marker for a range of
neuroendocrine tumors. In the present study, we observed that
CgA was significantly increased in patients with SCCC, as
previously reported in the literature. Moreover, our data showed
that CgA stained positive is an independent prognostic factor of
patients with SCCC (HR, 1.81; 95% CI, 1.12–2.91; P=0.015).
Table 1. Univariate and Multivariate Cox Logistic Analysis of Factors Associated with Survival.
Clinical Variable Subset Hazard ratio (95% CI) P value
Univariate analysis (n=293)
Age(years) $40 VS ,40 1.20 (0.87–1.66) 0.277
Tumor homology Pure VS Mixed 0.86 (0.54–1.35) 0.504
FIGO stage IIb–IV VS I–IIa 2.86 (2.06–3.98) ,0.001
Tumor mass size $4cm VS ,4cm 3.02 (1.78–5.13) ,0.001
Lymph no
de metastasis
Negative VS Positive 0.34 (0.22–0.55) ,0.001
Lymph-vascular space invasion Negative VS Positive 0.69 (0.38–1.25) 0.222
Depth of stromal invasion $2/3 VS ,2/3 2.43 (1.13–5.21) 0.022
Neurone-specific enolase Positive VS Negative 1.32 (0.66–2.65) 0.432
Chromogranin A Positive VS Negative 1.78 (1.02–2.52) 0.034
Synaptophysin Positive VS Negative 1.22 (0.99–1.47) 0.057
Multivariate analysis (n=293)
FIGO stage IIb–IV VS I–IIa 3.08 (2.05–4.63) ,0.001
Tumor mass size $4cm VS ,4cm 2.37 (1.28–4.36) 0.006
Chromogranin A Positive VS Negative 1.81 (1.12–2.91) 0.015
FIGO, International Federation of Gynecology and Obstetrics; CI, confidence interval. Bold indicates significant values.
doi:10.1371/journal.pone.0033674.t001
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cancers, such as Straughn JM et al reported that CgA stained
positive carried a significantly worse prognosis in patients with
SCCC; tumors from the long-term survivors stained negative for
CgA; patients with CgA -positive tumors were 21 times more likely
to die (RR=21.00) than patients negative for CgA (95% CI, 1.88–
233.00). [17]. Whereas most published studies regarding CgA
value on prostate cancer present encouraging results, Reis LO et al
reported serum CgA as prognostic factor in high-risk prostate
cancer [18]; CgA has been shown to correlate with disease
severity, tumor volume, tumor burden, and overall prognosis [19];
Berruti A et al also reported tissue CgA expression, evaluated in
prostate cancer needle biopsies at diagnosis, is an independent
prognostic factor of survival in prostate cancer patients [20].
Recently, Malaguarnera M et al reported that CgA serum level as
a marker of progression in hepatocellular carcinoma. patients with
higher CgA level had poor survival and showed poor prognosis,
compared to those with lower CgA level, the CgA is useful in
monitoring progression of disease and may assist as a prognostic
indicator [21]. A growing body of evidence suggests that CgA is
more than a diagnostic marker for cancer patients. but evaluated
as a significant prognostic marker in multiple human cancer.
Recent findings implicating CgA could play important roles in
tumor progression and response to therapy in cancer patients.
Further study is necessary to assess the role of this protein and its
fragments on the response to therapy and clarify the mechanisms
on tumor outcome.
In conclusion, the results of the present study demonstrate that
FIGO stage, tumor mass size and CgA stained may act as
surrogate for factors prognostic of survival. Specifically, CgA
stained positive should recommend to a novel marker useful in
prognostic assessment for patients with SCCC. Although this study
was retrospective in design and limited by the fact that the
majority of patients were extracted from small case series making it
difficult to validate the quality of information, it is the largest series
reported to date. We hope that our experience contributes to the
foundation of knowledge regarding this rare and aggressive tumor.
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